Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Mitoxantrone Hydrochloride Liposome
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diffuse Large B-cell Lymphoma
1 trial -
MoLuoDan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Precancerous Condition
1 trial -
Modified Wenxin Decoction
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Heart Failure
1 trial -
Mosunetuzumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Follicular Lymphoma
1 trial -
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
N-methyl glycine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Obsessive Compulsive Disorder
1 trial -
NALIRIFOX+Adebrelimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pancreatic Ductal Adenocarcinoma (PDAC)
1 trial -
NK cell perfusion group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Abortion, Missed
1 trial -
NK cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
NMDAE
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prodromal Schizophrenia
1 trial -
NMDAE
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Major Depressive Disorder
2 trials -
NMDAE
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Schizophrenia
2 trials -
NMDAE plus AIFA
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Schizophrenia
1 trial -
Nab-paclitaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinoma
1 trial -
Nab-paclitaxel Combined With Cadonilimab (AK104)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial -
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer (NSCLC)
1 trial -
Neu2000KWL
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stroke
1 trial -
NeuroEPO
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Parkinson Disease
1 trial -
Niraparib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ovarian Cancer
1 trial -
Nitric Oxide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pressure Ulcer
1 trial -
Nitrofurazone Group 1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Amyotrophic Lateral Sclerosis
1 trial -
Nivolumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Advanced Biliary Tract Cancer(BTC)
1 trial -
Obinutuzumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Marginal Zone Lymphoma
1 trial -
Obinutuzumab Injection [Gazyva]
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenia
2 trials
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources